Welcome to our dedicated page for VERU SEC filings (Ticker: VERU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERU's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERU's regulatory disclosures and financial reporting.
VERU INC. director Loren Mark Katzovitz received a grant of stock options covering 102,000 shares of common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029.
VERU INC. director Hyun Grace received a grant of options to buy 97,000 shares of common stock at an exercise price of $2.25 per share. These are compensation-related options, not an open-market purchase, and give her the right to buy shares in the future.
According to the vesting schedule, options for one-third of the shares vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, with all unexercised options expiring on May 4, 2036. After this grant, she holds options for 97,000 shares directly.
VERU INC. director Michael L. Rankowitz received a grant of options on 100,000 shares of Veru common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029.
VERU INC. director Lucy Lu reported receiving a grant of 104,000 common stock options as compensation. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, and Lu holds 104,000 options following this grant.
VERU INC. disclosed that Chief Scientific Officer K. Gary Barnette received a compensation-related grant of stock options. The award covers 160,000 options to acquire Veru common shares at an exercise price of $2.25 per share, with all options held directly after the grant.
According to the vesting terms, options for one-third of the shares vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, and the options expire on May 4, 2036. This filing reflects an equity incentive grant rather than an open-market purchase or sale.
VERU INC. Chief Corporate Officer Harry Fisch received a grant of stock options covering 160,000 shares of common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036.
According to the vesting schedule, one-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029. Following this grant, Fisch holds 160,000 options to acquire VERU common shares directly, reflecting a compensation-related equity award rather than an open-market purchase.
Veru Inc. registers up to $200,000,000 of common stock, debt securities, preferred stock, warrants, purchase contracts, rights and units from time to time under a shelf registration.
This prospectus provides a general description of the securities and states that specific terms, offering price and net proceeds will be set forth in a prospectus supplement. The offering is subject to completion and effectiveness and may be sold directly, through agents, dealers, or underwriters.
Veru Inc. filed a Registration Statement on Form S-3 to register 23,800,000 shares of common stock issuable upon exercise of warrants issued under a prospectus supplement dated October 29, 2025. The warrants consist of pre-funded warrants for 7,000,000 shares (exercise price $0.001), Series A warrants for 8,400,000 shares (exercise price $3.00) and Series B warrants for 8,400,000 shares (exercise price $3.00).
The pre-funded warrants are immediately exercisable with no expiration, Series A warrants expire five years from issuance, and Series B warrants expire upon the earlier of the third anniversary of issuance or certain clinical-data and trading-price triggers described in the prospectus. If all warrants are exercised for cash, aggregate proceeds to Veru would be approximately $50,407,000.